|
|
Application of HR-HPV,TCT combined with cervical biopsy under electronic colposcope respectively in the diagnosis of precancerous lesion of uterine cervix and cervical cancer |
YAN Qi HUANG Wen-jin ZENG Chao-yi WEN Hong-lei |
The Seventh People′s Hospital in Nanhai District of Foshan City in Guangdong Province,Foshan 528247,China |
|
|
Abstract Objective To explore the diagnostic value of high-risk human papillomavirus(HR-HPV)test,thinprep cytologic test(TCT)combined with cervical biopsy under electronic colposcope respectively in the diagnosis of precancerous lesion of uterine cervix and cervical cancer. Methods Four hundred medical records of TCT,electronic colposcope and cervical biopsy from January to December 2013 and 400 medical cases by HR-HPV,electronic colposcope and cervical biopsy from January to December 2014 were retrospectively analyzed,and the positive rate of two kinds of inspection method was compared. Results For the TCT,electronic colposcope and cervical biopsy,the positive rate of detection was 10.75%(43/400),while for HR-HPV,electronic colposcope and cervical biopsy,the positive rate of detection was 11.75% (47/400),and there was no statistical difference between two kinds of inspection method(P>0.05). Conclusion HR-HPV,electronic colposcope and cervical biopsy, and TCT,electronic colposcope and cervical biopsy have higher detection rate on precancerous lesions of uterine cervix and cervical cancer,which are beneficial for early detection and treatment of precancerous lesion of uterine cervix and cervical cancer,and are relatively ideal examination method.
|
|
|
|
|
Cite this article: |
YAN Qi,HUANG Wen-jin,ZENG Chao-yi, et al. Application of HR-HPV,TCT combined with cervical biopsy under electronic colposcope respectively in the diagnosis of precancerous lesion of uterine cervix and cervical cancer[J]. 中国当代医药, 2016, 23(2): 65-67.
|
|
|
|
URL: |
http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I2/65 |
[1] |
梁培琴,徐洁.液基细胞学检查联合电子阴道镜下宫颈活检诊断宫颈疾病77例临床分析[J].临床和实验医学杂志,2013,12(12):975-976.
|
[2] |
陈炎添,陈青龙,熊燕,等.HR-HPV DNA PCR联合TCT检测对宫颈癌前病变的诊断价值[J].检验医学,2013,28 (6):516-518.
|
[3] |
冯雅静,陈冬梅.TCT用于妇女病普查宫颈癌前病变的临床价值[J].继续医学教育,2015,29(3):96-97.
|
[4] |
刘红卫,李亚芙.高危型HPV检测联合液基细胞学在宫颈癌前病变筛查中的应用[J].陕西医学杂志,2010,39(6):674-675.
|
[5] |
丰颖,唐丽娟,曾良,等.HR-HPV、TCT联合电子阴道镜下宫颈活检在宫颈癌前病变及宫颈癌诊断中的应用[J].实用临床医学,2015,16(1):61-63,76.
|
[6] |
黄金兰.阴道镜联合TCT筛查宫颈病变的效果评价[J].吉林医学,2015,36(8):1577.
|
[7] |
周玉华.人乳头瘤病毒检测在宫颈癌前病变及宫颈癌筛查中的应用[J].山东医药,2011,51(8):92-93.
|
[8] |
黄桂凤,周霓,莫秀英,等.高危型HPV感染与宫颈癌前病变及宫颈癌的相关性分析[J].中国医药指南,2011,9 (18):12-13.
|
[9] |
鲁蓉,肖萤.超声弹性成像在宫颈癌前病变及宫颈癌诊断中的初步研究[J].中国现代医学杂志,2012,22(26):83-86.
|
[10] |
屠世晔.液基薄层细胞学联合高危型人乳头瘤病毒检测在宫颈癌前病变及宫颈癌诊断中的应用[J].中国基层医药,2013,20(9):1377-1378.
|
[11] |
姚永洪.液基薄层细胞学检测在宫颈癌前病变及宫颈癌诊断效果分析[J].中国基层医药,2013,20(5):752-753.
|
[12] |
刘勇鸿,路虹.液基薄层细胞学联合高危型人乳头瘤病毒检测对宫颈癌前病变及宫颈癌的诊断效果研究[J].河北医药,2013,35(12):1861-1862.
|
[13] |
刘微.细胞角蛋白与P16INK4a在宫颈癌前病变及宫颈癌中的研究进展[J].国际妇产科学杂志,2012,39(3):262-264.
|
[14] |
陆萍,祖木热来提·艾尼瓦尔,焦桢,等.人乳头状瘤病毒L1壳蛋白对宫颈癌前病变及宫颈癌的诊断价值分析[J].中国医药导报,2013,10(29):39-41.
|
[15] |
晋生,解胜兰,王冬梅,等.宫颈癌前病变及宫颈癌的早期社区干预[J].现代预防医学,2010,37(17):3244-3245,3247.
|
[16] |
林明.436例宫颈癌前病变及宫颈癌临床分析[J].中国医药指南,2011,9(30):72-73.
|
[17] |
朱永芹.电子阴道镜在宫颈疾病诊断中的临床价值[J].中国现代医生,2014,52(7):151-152,155.
|
|
|
|